Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center
Articles by Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center
Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
Practice Patterns and Real Use of Epcoritamab and Glofitamab
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the role of odronextamab.
Bispecific therapy – management of long-term adverse events in the community setting
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Bispecific therapy – treatment setting and management of short-term adverse events
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Management of CRS and ICANS with CAR T-cell Therapy
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.
Risk of Secondary Malignancies in Heavily Pre-Treated Population
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.
Current Approach to Bridging Therapy in R/R DLBCL
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART
Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.
Panel Discuses Use of CD19 Bispecifics in Sequencing
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.
Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.
Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.
Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.
Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning
ByMatthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Elizabeth Budde, MD, PhD,Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center,Frederick L. Locke, MD, Moffitt Cancer Center Medical experts highlight second-line options for treating patients with DLBCL.
Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices